SDC1 and neoplasm: Among them, circulating extracellular vesicles (EVs) enriched in CD138+ plasma cell markers, serum galectin-9, and soluble BCMA (sBCMA) have shown potential for detecting early relapse and capturing dynamic tumor changes; however, significant interassay variability and the absence of standardized thresholds limit their widespread use [22,34].